contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regulatory operations; ● expenses incurred under agreements with contract research org…
Reciprocal relationship from BNTX graph: Reciprocal relationship from MTNB graph: contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regu…
produce the clinical supplies of product necessary to conduct our previous clinical trials with MAT2203, we continue to explore relationships with well-respected third-party contract manufacturers fo…
Reciprocal relationship from ORANY graph: Reciprocal relationship from MTNB graph: produce the clinical supplies of product necessary to conduct our previous clinical trials with MAT2203, we continue…
s), Rezzayo (rezafungin, marketed byCorMedix Therapeutics), Brexafemme (Ibrexafungerp marketed by GlaxoSmithKline) and amphotericin B deoxycholate (marketed by X-Gen Pharmaceuticals, Inc.). There cur…
. The lease impairment charges were included in the impairment charges of other assets line in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2024. Th…
produce the clinical supplies of product necessary to conduct our previous clinical trials with MAT2203, we continue to explore relationships with well-respected third-party contract manufacturers fo…
Reciprocal relationship from ORANY graph: Reciprocal relationship from MTNB graph: produce the clinical supplies of product necessary to conduct our previous clinical trials with MAT2203, we continue…
Matinas BioPharma Holdings, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
MTNB-DEBT-11121
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
MTNB-DEBT-11120
Warrants outstanding: 238000
90%
xbrl warrant detail from xbrl 2025-12-31.
MTNB-DEBT
Debt stack $1.4M
90%
Market cache reports total debt of $1.4M.
Matinas BioPharma Holdings, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Matinas BioPharma Holdings, Inc..
Matinas BioPharma Holdings, Inc. Ownership
Holder
Name
Confidence
Evidence
MTNB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 28 tracked holders.
Matinas BioPharma Holdings, Inc. Extended Supply Chain Network